Applications of (2R,3S)-N-Benzoyl-3-Phenyl Isoserine in Industrial Manufacturing

As a certified chemical manufacturer, we supply (2R,3S)-N-Benzoyl-3-Phenyl Isoserine to advanced downstream industries where precise control over chiral input and stringent process validation are essential. We address real industrial needs in pharmaceutical synthesis, peptide drug APIs, chiral building blocks for specialty chemicals, and laboratory reference standards, ensuring direct manufacturing suitability and regulatory alignment for large-scale production.

1. Active Pharmaceutical Ingredient (API) Synthesis for Anticancer Drugs

Our (2R,3S)-N-Benzoyl-3-Phenyl Isoserine is widely adopted in the API manufacturing of third-generation anticancer agents, particularly in the synthesis of taxane derivatives. Pharmaceutical factories employ this raw material as a critical chiral intermediate for large-volume commercial routes, requiring high enantiomeric purity and controlled impurity profiles. The integration occurs in stages involving asymmetric synthesis and side-chain attachment under GMP conditions, supported by full batch traceability and analytical documentation for regulatory submission and product release.

Industry compliance standards

• ICH Q7 GMP for APIs
• European Pharmacopoeia (Ph. Eur.) monographs for chiral amino acid derivatives
• US FDA 21 CFR Part 210/211
• ICH Q3A/B impurity guidelines

Typical usage ratio

• Used at 1.2–1.5 molar equivalents relative to the parent core, finely adjusted according to batch size and yield targets

Downstream process integration

• Direct introduction during the esterification and acylation phases of taxane side-chain assembly, prior to final deprotection and crystallization

Final product types

• Paclitaxel (API)
• Docetaxel (API)
• Related taxane derivatives used in injectable formulations

2. Peptide Drug Intermediate for Peptidomimetic Synthesis

Leading peptide drug manufacturers employ our chiral intermediate for solid-phase or solution-phase coupling in peptidomimetic construction. The raw material ensures specific stereochemistry in final sequence assembly, delivering precise bioactivity and target specificity for next-generation peptide therapeutics. Stringent documentation and contaminant screening support regulatory filings, while batch-to-batch reproducibility supports high-throughput peptide plant operations.

Industry compliance standards

• USP General Chapter <1046> Peptide APIs
• GMP Peptide Manufacturing Guidelines (PICS, EMA)
• ISO 9001:2015 for process traceability
• EP (European Pharmacopoeia) General Text 5.2.1

Typical usage ratio

• Typically dosed at 1.05–1.2 molar equivalents per residue, with adjustment to maintain chain extension purity during scale-up

Downstream process integration

• Incorporated in automated peptide syntheses via protected amino acid coupling on resin or in bulk solution, prior to deprotection and cleavage

Final product types

• Long-acting peptide drugs for oncology and endocrinology
• Peptidomimetic APIs for biosimilar development
• Research-grade peptide standards

3. Chiral Auxiliary for Asymmetric Synthesis in Fine Chemical Production

Manufacturers of fine and specialty chemicals integrate our isoserine derivative as a chiral auxiliary to induce controlled stereochemistry during asymmetric transformations. This application enables the synthesis of specialty alcohols, acids, and pharmaceutical intermediates with high chiral fidelity, critical for downstream value chain partners with enantiomer-pure requirements. Collaboration with end-users often involves tailored impurity profiles and supply documentation to suit complex process audits or validation activities.

Industry compliance standards

• ISO 14001 environmental management (for solvent and waste control)
• REACH registration (EU)
• Chemical management per Chinese GB/T 39401-2020 (for market access in China)
• Responsible Care and Cefic SQAS (for European partners)

Typical usage ratio

• Incorporated at 1.0–1.3 equivalents relative to the reactive substrate, adapted based on the specific target product and kinetic yield

Downstream process integration

• Applied during enantioselective alkylation, reduction, or ring-closure steps as a covalently bound chiral source, removed after product formation via hydrolysis or crystallization

Final product types

• Enantiopure specialty alcohols and acids
• Chiral agrochemical precursors
• Non-API pharmaceutical intermediates

4. Analytical Reference Standard for Quality Control Laboratories

Accredited laboratories and pharmaceutical QC centers source our high-purity (2R,3S)-N-Benzoyl-3-Phenyl Isoserine as a reference material for method validation and routine HPLC or LC-MS quantification. Researchers use certified lots to verify process chirality, trace process impurities, and calibrate chiral separation protocols. Material documentation includes full COA, impurity analysis, and chromatographic methods as required by audit or regulatory inspection.

Industry compliance standards

• ISO/IEC 17025 for accredited testing laboratories
• USP and EP reference standard guidelines
• OECD Good Laboratory Practice (GLP)
• FDA cGMP Section 211.194 for test records

Typical usage ratio

• Introduced at 0.1–5.0 mg per analytical run, according to standard curve requirements and sensitivity levels

Downstream process integration

• Employed as calibration standard for enantiomeric purity confirmation, method qualification, and impurity profiling across synthetic biology, pharmaceutical QC, and academic research labs

Final product types

• Certified analytical standards
• QC-approved chromatographic columns
• Method validation reports for regulatory submissions